Immunobiology of influenza vaccines

Chest

Volumn 143, Issue 2, 2013, Pages 502-510

  Gomez Lorenzo, Margarita M ^a   Fenton, Matthew J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

AGE; ANTIGEN SPECIFICITY; ARTICLE; CROSS REACTION; DNA MICROARRAY; DNA POLYMORPHISM; DRUG MEGADOSE; GENE EXPRESSION; GENE IDENTIFICATION; HEALTH STATUS; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INNATE IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH; SEASONAL INFLUENZA; SYSTEMS BIOLOGY; SYSTEMS VACCINOLOGY; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 84874078380     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1711     Document Type: Article

References (75)

1. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044): 850-856.
2. Rao SS, Kong WP, Wei CJ, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE. 2010; 5 (3): e9812.
3. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010; 33 (4): 516-529.
4. Belshe RB, Walker R, Stoddard JJ, Kemble G, Maassab HF, Mendelman PM. Influenza vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008: 291-309.
5. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008; 26 (suppl 4): D35-D40.
6. Banzhoff A, Gasparini R, Laghi-Pasini F, et al; MF59- adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE. 2009; 4 (2): e4384.
7. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine. 2005; 23 (suppl 1): S26-S38.
8. Busse WW, Peters SP, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol. 2011;127(1): 130-137.
9. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human uenza memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009; 106 (19): 7962-7967.
10. Smith GJ, Bahl J, Vijaykrishna D, et al. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A. 2009; 106 (28): 11709-11712.
11. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006; 43 (9): 1135-1142.
12. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007; 370 (9587): 580-589.
13. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011; 3 (85): 85ra48.
14. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther. 2010; 32 (13): 2186-2197.
15. Gillard P, Caplanusi A, Knuf M, et al. An assessment of prime-boost vaccination schedules with AS03(A)-adjuvanted prepandemic H5Nl vaccines: a randomized study in European adults [published online ahead of print March 9, 2012]. Influenza Other Respi Viruses. doi:10.1111/j.1750- 2659.2012.00349.x.
16. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108-6113.
17. Chen Z, Wang W, Zhou H, et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol. 2010; 84 (1): 44-51.
18. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005; 23 (8): 1029-1036.
19. Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol. 2009;333:227-241.
20. Bucasas KL, Franco LM, Shaw CA, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis. 2011; 203 (7): 921-929.
21. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12(8):786-795.
22. Smith W, Andrewes CH, L aidlaw PP. A virus obtained from influenza patients. Lancet. 1933; 222 (5732): 66-68.
23. Stokes J, Chenoweth AD, Waltz AD, Gladen RG, Shaw D. Results of immunization by means of active virus of human influenza. J Clin Invest. 1937; 16 (2): 237-243.
24. Members of the Commission on Influenza, Board for the Investigation and Control of Influenza and Other Epidemic Diseases in the Army, Preventive Medicine Service, Office of the Surgeon General, United States Army. A clinical evaluation of vaccination against influenza: preliminary report. JAMA. 1944; 124 (14): 982-985.
25. Davenport FM. Current knowledge of influenza vaccine. JAMA. 1962; 182 (1): 11-13.
26. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010; 363 (21): 2036-2044.
27. Kaminski DA, Lee FE. Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front Immunol. 2011;2:76.
28. Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol. 1998; 72 (11): 8682-8689.
29. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol. 2006;7(5): 449-455.
30. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004; 59 (1): 1-15.
31. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361 (20): 1945-1952.
32. Cox NJ, Subbarao K. Influenza. Lancet. 1999; 354 (9186): 1277-1282.
33. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006; 194 (suppl 2): S111-S118.
34. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol. 2001;260:171-190.
35. Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008: 259-290.
36. Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol. 1982; 116 (2): 212-227.
37. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect. 1989; 102 (2): 325-333.
38. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J. 1973; 49 (569): 159-163.
39. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972; 70 (4): 767-777.
40. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modifica tion of an outbreak of influenza in Tecumseh, Michigan by vac cination of schoolchildren. J Infect Dis. 1970; 122 (1-2): 16-25.
41. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999; 281 (10): 908-913.
42. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997; 15 (10): 1114-1122.
43. Bell DM; World Health Organization Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006; 12 (1): 81-87.
44. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59 (RR-8): 1-62.
45. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002; 15 (2): 295-323.
46. Kreijtz JH, Suezer Y, de Mutsert G, et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS ONE. 2009; 4 (11): e7790-e7790.
47. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol. 2010; 84 (7): 3201-3209.
48. Schwartz JA, Buonocore L, Suguitan AL Jr, et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol. 2010; 84 (9): 4611-4618.
49. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev Vaccines. 2009; 8 (4): 469-481.
50. DiNapoli JM, Nayak B, Yang L, et al. Newcastle disease virusvectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 2010; 84 (3): 1489-1503.
51. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine. 1993; 11 (3): 293-306.
52. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010; 28 (suppl 3): C25-C36.
53. Seubert A, Calabro S, Santini L, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 infl ammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A. 2011; 108 (27): 11169-11174.
54. Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ. Infl ammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci U S A. 2011; 108 (7): 2927-2932.
55. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine. 2012; 30 (29): 4341-4348.
56. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29 (13): 2461-2473.
57. Mischler R, Metcalfe IC. Inflexal ® V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002; 20 (suppl 5): B17-B23.
58. Livingston BD, Higgins D, Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs. 2006; 20 (6): 335-340.
59. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004; 103 (1-2): 173-176.
60. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza Vaccine. Nat Med. 2010; 16 (12): 1389-1391.
61. Wrammert J, Koutsonanos D, Li GM, et al. Broadly crossreactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208 (1): 181-193.
62. Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012; 109 (23): 9047-9052.
63. Corti D, Suguitan AL Jr, Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010; 120 (5): 1663-1673.
64. Kitano H. Computational systems biology. Nature. 2002; 420 (6912): 206-210.
65. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol. 2005; 3 (4): 281-294.
66. Lund JM, Alexopoulou L, Sato A, et al. Recognition of singlestranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004; 101 (15): 5598-5603.
67. Geiss GK, Salvatore M, Tumpey TM, et al. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A. 2002; 99 (16): 10736-10741.
68. Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008; 105 (30): 10501-10506.
69. Ramilo O, Allman W, Chung W, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood. 2007; 109 (5): 2066-2077.
70. Zaas AK, Chen M, Varkey J, et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe. 2009; 6 (3): 207-217.
71. Huang Y, Zaas AK, Rao A, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. PLoS Genet. 2011; 7 (8): e1002234.
72. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-125.
73. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011; 121 (8): 3109-3119.
74. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. O MICS. 2011; 15 (9): 625-636.
75. Dolgin E. Trial designs for vaccines adapt to the times. Nat Med. 2012; 18 (3): 327.